摘要
目的:探讨c-erbB-2和DNA拓扑异构酶Ⅱα(DNA topoisomeraseⅡα,TopoⅡα)在乳腺癌中的表达及其和临床病理的关系。方法:采用免疫组化法检测72例乳腺癌石蜡切片标本中c-erbB-2和TopoⅡα的表达。结果:c-erbB-2和TopoⅡα在乳腺癌的阳性表达率分别为29.2%(21/72)和59.7%(43/72),其中c-erbB-2在淋巴结有无转移之间、在雌、孕激素受体表达均阳性与均阴性之间表达差异有统计学意义(P<0.05);TopoⅡα在雌、孕激素受体表达均阳性与均阴性之间表达差异有统计学意义(P<0.05)。结论:c-erbB-2可以作为判断乳腺癌患者预后的有效指标,TopoⅡα在乳腺癌中的表达可作为指导乳腺癌化疗的重要指标和判断乳腺癌预后的参考指标。
Objective： To evaluate the clinicopathological significance of expressions of c-erbB-2, DNA to- poisomerase Ⅱα（Topo Ⅱα） in breast cancer. Methods： seventy-two cases of paraffin-embedded specimens of breast carcinoma were studied by immunohistochemical technique. Results： The positive rates of c-erbB-2 and Topo Ⅱα were 29, 2% （21/72）, 59. 7 % （43/72） respectively. The expressions of c-erbB-2 were positively correlated with lymph node metastases and both ER（＋） and PR（＋） （P d0.05）, but the expressions of TopoⅡα, were positively correlated with both ER（＋） and PR（＋） breast cancer tissues （P〈 0.05）. Conclusions： The results suggested that c-erbB-2 can be an effective marker for estimating the prognosis of breast cancer. The expressions of TopoⅡα may be useful in predicting prognosis and guiding chemotherapy.
出处
《新疆医科大学学报》
CAS
2008年第1期42-44,共3页
Journal of Xinjiang Medical University
